Alisol B 23-acetate intervened the downstream regulators of FXR such as SREBP1c, PPARα, and genes involved in triglyceride metabolism (ApoC-II, ApoC-III, and angiopoietin like ANGPTL3), contributing to the improvement of hyperlipidemia as well as hepatic steatosis. This evidence concerns the gene APOC3 and fatty liver disease.